IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Authors :: Olivier Demaria
Guillaume Habif
François Le Floch
Laura Chiossone
Romain Remark
Marie Vetizou
Nadia Maurel
Laurent Gauthier
Yannis Morel
Carine Paturel
Eric Vivier
Pascale Andre
Innate Pharma
Centre d'Immunologie de Marseille - Luminy (CIML)
Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Assistance Publique - Hôpitaux de Marseille (APHM)
Source :: Blood, Blood, 2022, 140 (Supplement 1), pp.11559-11559. ⟨10.1182/blood-2022-163561⟩
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.
Abstract: International audience

Subjects :: [SDV]Life Sciences [q-bio]
Immunology
Cell Biology
Hematology
Biochemistry

Tools